CAR-T Cell Therapy Market is expected to reach US$ 20.4 billion by 2033 | Top key players - Novartis AG, Gilead Sciences, Inc., Company.

Market Size and Growth:

The Global CAR-T Cell Therapy Market reached US$ 4.8 billion in 2024 and is expected to reach US$ 20.4 billion by 2033, growing at a CAGR of 16.3% during the forecast period 2025-2033.

CAR-T Cell Therapy Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/car-t-cell-therapy-market?sz

The CAR-T Cell Therapy Market refers to the biotechnology sector focused on developing and commercializing Chimeric Antigen Receptor (CAR) T-cell therapies. These therapies involve modifying patients' T-cells to target and destroy cancer cells, offering personalized treatment for hematologic malignancies and solid tumors. The market encompasses research, clinical trials, regulatory approvals, manufacturing, and commercialization of innovative CAR-T therapies.

Recent Key Developments of USA and Japan:

USA:

June 2025: Johnson & Johnson and Legend Biotech announced that 33% of patients with relapsed or refractory multiple myeloma treated with CARVYKTI® remained progression-free for over five years, from the CARTITUDE-1 clinical trial.

August 2025: A Phase 1 clinical trial for a "Triple Threat" CAR-T cell therapy was launched at the University of Kansas Cancer Center. It targets three antigens (CD19, CD20, and CD22) simultaneously to combat resistance in B-cell malignancies.

Japan:

July 2025: AGC Biologics expanded its cell therapy operations by commencing clinical manufacturing services in Yokohama, a step towards serving the growing Asian market for autologous and allogeneic products.

July 2025: Noile-Immune's project for a solid tumor CAR-T cell therapy was adopted for subsidies by Yamaguchi Prefecture and Ube City.

Market Key Players:

Novartis AG
Gilead Sciences, Inc.
Bristol Myers Squibb company
Johnson & Johnson
Autolus Therapeutics
Pfizer Inc.
BioNTech SE.
Merck KGaA
Allogene Therapeutics
Atara Biotherapeutics, Inc.

Growth Forecast Projected:

The Global CAR-T Cell Therapy Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global CAR-T Cell Therapy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=car-t-cell-therapy-market

Market Segmentation:

By Therapy Type: Autologous CAR-T Cell Therapy, Allogeneic CAR-T Cell Therapy.

By Drug Type: Abecma, Breyanzi, Carvykti, Tecartus, Kymriah, Yescarta.

By Target Antigen: CD19, BCMA (B-cell maturation antigen), CD20, CD22, CD30, CD33, GD2, HER2, Others.

By Application: Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma, Others.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/car-t-cell-therapy-market

Benefits of the Report:

âž¡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

âž¡ Top-down and bottom-up approach for regional analysis

âž¡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

âž¡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

âž  How big is the CAR-T Cell Therapy market?

âž  Who are the key players in the CAR-T Cell Therapy market?

âž  What is the projected growth rate of the CAR-T Cell Therapy market?

âž  What is the market forecast for the CAR-T Cell Therapy industry by 2033?

âž  Which region is estimated to dominate the CAR-T Cell Therapy market through the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.